Arthur Bergman

5.5k citations

70 papers · 3.6k indexed · h-index 31

Impact in

Endocrinology, Diabetes and Metabolism top 0.5%
- Diabetes Treatment and Management
- Diabetes Management and Research
Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism

Papers in

Endocrinology, Diabetes and Metabolism 35
- Diabetes Treatment and Management 30
- Diabetes Management and Research 7
Pharmacology 12
- Pharmacogenetics and Drug Metabolism 11
- Pharmacology and Obesity Treatment 6

Co-authors: Gary Herman John A. Wagner Bingming Yi John F. Paolini Paul Statkevich Teddy Kosoglou Amy O. Johnson‐Levonas Karen Snyder
Journals: Clinical Pharmacology & Therapeutics (13 papers)The Journal of Clinical Pharmacology (12 papers)Xenobiotica (5 papers)Drug Metabolism and Disposition (4 papers)Journal of Hepatology (4 papers)
Partner nations: United States Belgium United Kingdom

In The Last Decade

Arthur Bergman

68 papers receiving 3.5k citations

Peers

Countries citing papers authored by Arthur Bergman

Since Specialization

Citations

This map shows the geographic impact of Arthur Bergman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur Bergman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur Bergman more than expected).

Fields of papers citing papers by Arthur Bergman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur Bergman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur Bergman. The network helps show where Arthur Bergman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Arthur Bergman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Arthur Bergman Line = papers co-authored together Arthur Bergman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Flecainide for the Treatment of Andersen-Tawil Syndrome JACC. Clinical electrophysiology ·Tomer Mann, Holly Maples, Vadim Yapiyev, Arthur Bergman, Lin Jia, Christian van der Werf, Michael H. Gollob, Jason D. Roberts, Habib Khan, Shubhayan Sanatani, Vasanth Vedantham, Byron K. Lee, HA Snyman, Andrew D. Krahn, Rafik Tadros, Arthur A.M. Wilde, Michael J. Ackerman, Melvin M. Scheinman	2025	0
2	Study of the ketohexokinase inhibitor PF‐06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy Clinical and Translational Science ·Ruolun Qiu, Kari R. Fonseca, Arthur Bergman, Jian Lin, David A. Tess, Lauren A. Newman, S. Rappaport, Zivile Useckaite, Andrew Rowland, Manoli Vourvahis, David Rodrigues	2023	1
3	Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans Xenobiotica ·Tim F. Ryder, Arthur Bergman, Amanda King‐Ahmad, Neeta B. Amin, Manjinder S. Lall, T. Eric Ballard, Amit S. Kalgutkar	2022	3
4	Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug Development Clinical Pharmacology & Therapeutics ·Ravi Shankar Prasad Singh, Gregory S. Walker, Eugene P. Kadar, Loretta M. Cox, Heather Eng, Raman Sharma, Arthur Bergman, Lien Van Eyck, Frances Hackman, Sima S. Toussi, Amit S. Kalgutkar, R. Scott Obach	2022	15
5	Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial Med ·David J. Kazierad, Kristin Chidsey, Veena Somayaji, Arthur Bergman, Morris J. Birnbaum, Roberto A. Calle	2021	54
6	A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus Diabetes Research and Clinical Practice ·Arthur Bergman, Laura Elice de Souza Ferreira Miranda, Veena Somayaji, Roberto A. Calle, David J. Kazierad	2017	21
7	Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males British Journal of Clinical Pharmacology ·Gary Herman, Goutam C. Mistry, Bingming Yi, Arthur Bergman, Amy Q. Wang, Wei Zeng, Li Chen, Karen Snyder, Jon Ruckle, Patrick Larson, Michael J. Davies, Ronald B. Langdon, Keith Gottesdiener, John A. Wagner	2010	29
8	Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans Drug Metabolism and Disposition ·Sanjeev Kumar, 阿部聡, Georgy Hartmann, Jiashun Liu, Arthur Bergman, Muhammad Zaid Ramadhan, Jonathan Z. Ho, E.N. Shulga, Becerra Juan Luis, Matthew P. Braun, Bindhu V. Karanam, Dennis Dean, Isaias Noel Gendrano, B.L. Ioffee, John A. Wagner, Rajesh Krishna	2009	33
9	Sitagliptin, an dipeptidyl peptidase‐4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects British Journal of Clinical Pharmacology ·Goutam C. Mistry, Arthur Bergman, Wei Zheng, David Hreniuk, Miguel A. Zinny, Keith Gottesdiener, John A. Wagner, Gary Herman, Marcella Ruddy	2008	42
10	Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects The Journal of Clinical Pharmacology ·Rajesh Krishna, Arthur Bergman, Patrick Larson, Josée Côté, Kenneth C. Lasseter, Cheryl Ferrell, Amy Wang, Wei Zeng, Li Chen, John A. Wagner, Gary Herman	2007	56
11	Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies The Lancet ·Rajesh Krishna, Matt S. Anderson, Arthur Bergman, Bo Jin, Mei-Song Liao, Josée Côté, Kim Rosko, C.M. Chavez-Eng, Ryan Lutz, Daniel M. Bloomfield, María J. Gutiérrez, James Doherty, 赵伟卓, Jeffrey Chodakewitz, Keith Gottesdiener, John A. Wagner	2007	206
12	Dose‐proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers Biopharmaceutics & Drug Disposition ·Arthur Bergman, Goutam C. Mistry, Wen‐Lin Luo, 正則江藤, Julie A. Stone, Amy Wang, Wei Zeng, Li Chen, Stacy C. Dilzer, Kenneth C. Lasseter, Gary Herman, John A. Wagner, Rajesh Krishna	2007	14
13	Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects The Journal of Clinical Pharmacology ·Arthur Bergman, Joanne Burke, Patrick Larson, Ana de Oliveira Guilherme Buzanich, Larisa Reyderman, Paul Statkevich, Teddy Kosoglou, Howard Greenberg, Walter K. Kraft, Gb Ambrosio, Gail Murphy, Keith Gottesdiener, John F. Paolini	2006	23
14	Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers The Journal of Clinical Pharmacology ·Anup Majumdar, Laura Howard, Michael R. Goldberg, Lisa Hickey, M.L. Constanzer, Paul Rothenberg, Jennifer D. Naughton, Deborah Panebianco, Thomas E. Bradstreet, Arthur Bergman, Scott A. Waldman, Howard Greenberg, Kathleen Butler, C. Nijland, Inge De Lepeleire, N. Michiels, Kevin J. Petty	2006	84
15	Effect of Impaired Renal Function and Haemodialysis on the Pharmacokinetics of Aprepitant Clinical Pharmacokinetics ·Arthur Bergman, Thomas Marbury, Jeih-weili Hung, Suzanne K. Swan, Lisa Hickey, Thomas E. Bradstreet, John M. Busillo, Kevin J. Petty, NP Thorne, M.L. Constanzer, Su-Er W. Huskey, Anup Majumdar	2005	23
16	Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses Clinical Pharmacology & Therapeutics ·Gary Herman, C. Melinda Stevens, Koen Vandyck, Arthur Bergman, Bingming Yi, М. Чегерев, Karen Snyder, D Hilliard, Michael Tanen, Wesley Tanaka	2005	414
17	Ezetimibe Clinical Pharmacokinetics ·Teddy Kosoglou, Paul Statkevich, Amy O. Johnson‐Levonas, John F. Paolini, Arthur Bergman, Kevin B. Alton	2005	364
18	Binding of brominated diphenyl ethers to male rat carrier proteins Xenobiotica ·Heldur Hakk, G. Larsen, Arthur Bergman, Ulrika Örn	2002	16
19	Metabolism, excretion and distribution of the flame retardant tetrabromobisphenol-A in conventional and bile-duct cannulated rats Xenobiotica ·Heldur Hakk, G. Larsen, Arthur Bergman, Ulrika Örn	2000	65
20	Polybrommated diphenyl ethers (PCDs) as Ah-receptor agonists and antagonists. Socio-Environmental Systems Modeling ·Ilonka A.T.M. Meerts, M. J. Robles Raya, Dario Antognozzi, Eva Jakobsson, Arthur Bergman, Abraham Brouwer	1998	34

About Arthur Bergman

Arthur Bergman is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology, Oncology, Transplantation and Pharmacology, having authored 70 papers that have together received 3.6k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (30 papers), Peptidase Inhibition and Analysis (13 papers), Drug Transport and Resistance Mechanisms (13 papers), Pharmacogenetics and Drug Metabolism (11 papers), Lipoproteins and Cardiovascular Health (7 papers), Diabetes Management and Research (7 papers), Liver Disease Diagnosis and Treatment (7 papers) and Pharmacology and Obesity Treatment (6 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.9k citations), Pharmacology (404 citations), Oncology (1.0k citations), Surgery (1.2k citations) and Transplantation (71 citations). Arthur Bergman has collaborated with scholars based in United States, Belgium and United Kingdom. Frequent co-authors include Gary Herman, John A. Wagner, Bingming Yi, John F. Paolini, Paul Statkevich, Teddy Kosoglou, Amy O. Johnson‐Levonas, Karen Snyder, Michael Tanen and Wesley Tanaka. Their work appears in journals such as Clinical Pharmacology & Therapeutics, The Journal of Clinical Pharmacology, Xenobiotica, Drug Metabolism and Disposition and Journal of Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact